Overview

Omalizumab in the Treatment of Peanut Allergy

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if treatment with omalizumab (Xolair, anti-IgE) can eliminate or reduce symptoms of peanut allergy.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Omalizumab